Profil bibliographique

Adrien Contejean

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

78Publications signalées

1062Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Acute Myeloid Leukemia ResearchNeutropenia and Cancer InfectionsMultiple Myeloma Research and TreatmentsAntibiotics Pharmacokinetics and EfficacyChronic Lymphocytic Leukemia Research

Publications récentes

Accès ouvert 2026 articleOpenAlex

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry

Maël Heiblig, Zofia Gross, Amine Belhabri, Urbain Tauveron-Jalenques et autres

0 citationsLeukemia

Accès ouvert 2026 articleOpenAlex

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group

Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Zofia Gross, Emmanuelle Tavernier et autres

1 citationBone Marrow Transplantation

Accès ouvert 2026 articleOpenAlex

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3 ‐Mutated AML : A FILO ‐ DATAML ‐ PETHEMA Real‐World Study

Gaspar Aspas Requena, Pau Montesinos, E. Berard, Sarah Bertoli et autres

1 citationAmerican Journal of Hematology

Accès ouvert 2025 conference-abstractOpenAlex

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Gaspar Aspas Requena, Pedro Chorão, Samy Chraïbi, Urbain Tauveron-Jalenques et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Maël Heiblig, Urbain Tauveron-Jalenques, Martin Carré, Amine Belhabri et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

Pierre Péterlin, Maël Heiblig, Stéphane Morisset, Sarah Bertoli et autres

1 citationBlood

2025 conference-abstractOpenAlex

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Sylvain Garciaz, Louison Brac de la Perriere, Sarah Bertoli, Urbain Tauveron-Jalenques et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Maël Heiblig, Pierre Péterlin, Stéphane Morisset, Pierre‐Yves Dumas et autres

0 citationsBlood

2025 articleOpenAlex

Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome

Romain Stammler, Alexandre Vallée, Julien Rohmer, Nathalie Grardel et autres

3 citationsThe Journal of Allergy and Clinical Immunology In Practice

Accès ouvert 2025 preprintOpenAlex

Intensive Chemotherapy with or without Midostaurin in Adults ≥60 years old with FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, Sarah Bertoli et autres

0 citationsResearch Square

Accès ouvert 2024 articleOpenAlex

Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm

Sabine Khalife‐Hachem, Arnaud Pagès, Elie Akoury, Sarah Bonnet et autres

6 citationsBlood Advances

2024 conference-abstractOpenAlex

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Martin Carré, Mathieu Meunier, Zofia Gross, Gaspar Aspas Requena et autres

2 citationsBlood

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.